Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables declines year over year

Q1 FY2026 accounts payables of $1.88M (cash outflow) fell 1.6% year over year, ahead of the -608.8% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +124.3% a year.

Context

  • Accounts payables amounted to 32.3% of revenue in FY2025, down 14.9 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.6% holds above the trailing-twelve-month pace of -608.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.88M-247.8% QoQ
Last fiscal yearDec 2025
-$3.92M-218.5% YoY
LTMMar 2026
-$3.89M-608.8% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year-218.5%——
3-year CAGR+124.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(3.92M) USD
Year-over-year change
-218.5%

Accounts Payables vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -608.8% is the lowest of 10, against a peer median of +38.3%.
  • Accounts payables amounts to 23.2% of revenue for PRLD, versus a peer median of 12.4%.
PRLD Competitors
Accounts Payables for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$3.89M USD-608.8%+124.3%23.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$3.31M USD+280.1%+21.9%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$3.06M USD-161.7%—9.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.51M USD+12.5%—1116.0%
IVAInventiva S.A.FY2025€2.46M EUR—-11.4%54.8%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.14M USD+288.2%—15.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$793K USD-49.2%-33.2%2.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$399K USD+1230.0%-34.4%0.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$370K USD-77.8%—3.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$325K USD+38.3%-33.1%550.8%
IMRXImmuneering CorporationLTM Mar 2026$197.49K USD+121.5%——
Peer median (excluding PRLD) —+38.3%-33.1%12.4%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.